Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8595169 | 0.80 | SIRT1 (0.50) | SMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL3258128 | 0.79 | SIRT1 (0.63) | SMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL11848642 | 0.79 | KDM4E (0.50) | ALOX15SIRT2SIRT1 | |
| SCHEMBL8632140 | 0.77 | SIRT2 (0.37) | TSPOSIRT2SIRT1 | |
| SCHEMBL11844570 | 0.76 | SIRT2 (0.43) | TP53ALOX15SIRT2SIRT1 | |
| SCHEMBL11843108 | 0.75 | KDM4E (0.48) | LMNA | |
| Sulfuric Acid SCHEMBL8592514 | 0.75 | SIRT1 (0.57) | SMN1; SMN2SIRT2SIRT1 | |
| SCHEMBL4763963 | 0.74 | NR2E1 (0.52) | LMNATP53ALOX15 | |
| SCHEMBL11835576 | 0.74 | GABRA1 (0.44) | SIRT2SIRT1 | |
| SCHEMBL8574636 | 0.74 | SIRT2 (0.42) | SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621544-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE Healthcare UK Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041953-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |